Abstract
ObjectiveTo compare the treatment efficacy and safety of tofacitinib (TOF) versus methotrexate (MTX) in Takayasu arteritis (TAK).MethodsFifty-three patients with active disease from an ongoing prospective TAK cohort in China were included in this study. Twenty-seven patients were treated with glucocorticoids (GCs) and TOF, and 26 patients were treated with GCs with MTX. The observation period was 12 months. Complete remission (CR), inflammatory parameter changes, GCs tapering and safety were assessed at the 6th, 9th and 12th month. Vascular lesions were evaluated at the 6th and 12th month, and relapse was analysed during 12 months.ResultsThe CR rate was higher in the TOF group than in the MTX group (6 months: 85.19% vs 61.54%, p=0.07; 12 months: 88.46% vs 56.52%, p=0.02). During 12 months’ treatment, patients in the TOF group achieved a relatively lower relapse rate (11.54% vs 34.78%, p=0.052) and a longer median relapse-free duration (11.65±0.98 vs 10.48±2.31 months, p=0.03). Average GCs dose at the 3rd, 6th and 12th month was lower in the TOF group than that in the MTX group (p<0.05). A difference was not observed in disease improvement or disease progression on imaging between the two groups (p>0.05). Prevalence of side effects was low in both groups (3.70% vs 15.38%, p=0.19).ConclusionTOF was superior to MTX for CR induction, a tendency to prevent relapse and tapering of the GCs dose in TAK treatment. A good safety profile for TOF was also documented in patients with TAK.
Funder
Clinical Research Project of Zhongshan Hospital
China Postdoctoral Science Foundation
National Natural Science Foundation of China
Science and Technology Commission of Shanghai Municipality
Youth Research Fund of Zhongshan Hospital, Fudan University
Subject
General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology
Reference30 articles.
1. Takayasu arteritis: advanced understanding is leading to new horizons;Tombetti;Rheumatology,2019
2. Takayasu arteritis: recent developments;Zaldivar Villon;Curr Rheumatol Rep,2019
3. Update of the EULAR recommendations for the management of large vessel vasculitis;Hellmich;Ann Rheum Dis,2018
4. Management of large-vessel vasculitis;Salvarani;Curr Opin Rheumatol,2019
5. Non-Glucocorticoid drugs for the treatment of Takayasu's arteritis: a systematic review and meta-analysis;Barra;Autoimmun Rev,2018
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献